Table 2.
Metastatic PDAC patient characteristics at the time of blood draw for CTC purification.
| ID | Age | Sex | CA19-9 (U/mL) | CEA (ng/mL) | Treatment status |
|---|---|---|---|---|---|
| metPDAC01 | 57 | M | 7 | 1.1 | Responding |
| metPDAC02 | 49 | F | 117 | 4.8 | Responding |
| metPDAC03 | 53 | F | 706 | 5.5 | Progressing |
| metPDAC04 | 58 | F | 1307 | 54 | Responding |
| metPDAC05 | 66 | F | 7268 | 2.6 | Progressing |
| metPDAC06 | 55 | M | 4 | – | Progressing |
| metPDAC07 | 60 | M | 354 | 2.9 | Responding |
| metPDAC08 | 66 | M | 355 | 3.4 | Responding |
| metPDAC09 | 70 | F | 18 | 1.5 | Responding |
| metPDAC10 | 75 | F | <1 | 11 | Responding |
| metPDAC11 | 49 | M | 32 | 6.4 | Responding |
| metPDAC12 | 66 | M | 174 | 19 | Responding |
| metPDAC13 | 71 | F | 39 | 5 | Progressing |
| metPDAC14 | 70 | F | 54 | 9.9 | Progressing |
| metPDAC15 | 71 | F | 49 | 1.6 | Responding |
| metPDAC16 | 79 | F | 19 | – | Responding |
| metPDAC17 | 67 | M | 593 | 4.2 | Naive |
| metPDAC18 | 68 | F | 39 | 2 | Naive |